Market Overview

RBC Capital Upgrades AVEO Pharmaceuticals To Sector Perform


Analysts at RBC Capital upgraded AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from Underperform to Sector Perform.

The price target for AVEO Pharmaceuticals has been raised from $2.00 to $3.00.

AVEO Pharmaceuticals shares have dropped 22.28% over the past 52 weeks, while the S&P 500 index has surged 10.34% in the same period.

AVEO Pharmaceuticals' shares climbed 14.67% to $1.72 in pre-market trading.

Latest Ratings for AVEO

Feb 2019DowngradesBuyNeutral
Feb 2019DowngradesBuyNeutral
Jan 2019Initiates Coverage OnOutperform

View More Analyst Ratings for AVEO
View the Latest Analyst Ratings

Posted-In: RBC CapitalUpgrades Analyst Ratings


Related Articles (AVEO)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

JMP Securities Upgrades DR Horton To Market Outperform

EUR/USD Steady